Stock Analiz

TransMedics Group, Inc. (TMDX) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

TransMedics Group’s revenue went from $15M in fiscal 2018 to $605M in fiscal 2025, growth of about 70.2% a year.

Net income in fiscal 2025 was $190M, a net margin of 31.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $728M and net income $144M.

Free cash flow was $134M in fiscal 2025 and positive in 1 of the 8 years shown.

The diluted share count rose 2884% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2018: $15M20182019: $26M20192020: $28M20202021: $31M20212022: $93M20222023: $242M20232024: $442M20242025: $605M2025$605M
Net income
2018: -$24M20182019: -$34M20192020: -$29M20202021: -$44M20212022: -$36M20222023: -$25M20232024: $35M20242025: $190M2025$190M
Free cash flow
2018: -$26M20182019: -$32M20192020: -$31M20202021: -$32M20212022: -$58M20222023: -$165M20232024: -$81M20242025: $134M2025$134M
EPS (diluted)
2018: $-17.4820182019: $-2.3620192020: $-1.1620202021: $-1.6020212022: $-1.2320222023: $-0.7720232024: $1.0120242025: $4.872025$4.87

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$728M$605M$442M$242M$93M$31M$28M$26M$15M
Gross profit$426M$363M$262M$154M$65M$21M$17M$14M$6M
Operating income$86M$109M$37M-$29M-$31M-$39M-$26M-$30M-$20M
Net income$144M$190M$35M-$25M-$36M-$44M-$29M-$34M-$24M
EPS (diluted)$3.66$4.87$1.01$-0.77$-1.23$-1.60$-1.16$-2.36$-17.48
R&D$106M$69M$56M$36M$27M$22M$19M$20M$14M
Revenue growth—+37.1%+82.7%+158.5%+197.8%+10.7%+9.7%+76.3%—

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$112M$193M$49M-$13M-$46M-$29M-$30M-$32M-$26M
Capital spending-$68M-$59M-$130M-$152M-$12M-$4M-$455000-$165000-$418000
Free cash flow$45M$134M-$81M-$165M-$58M-$32M-$31M-$32M-$26M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$41M$37M$33M$20M$10M$7M$2M$854000$144000

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$489M$337M$395M$201M$92M$126M$81M$20M
Debt—$470M$459M$457M$69M$44M$35M$35M$35M
Equity—$473M$229M$137M$187M$68M$104M$55M-$192M
Total assets—$1.1B$804M$706M$277M$135M$152M$105M$42M
Shares (diluted)41M41M35M33M30M28M25M14M1M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin58.6%59.9%59.4%63.8%69.8%67.4%58.7%53.6%39.1%
Operating margin11.9%17.9%8.5%-11.9%-33.6%-125.6%-93.0%-114.5%-138.1%
Net margin19.9%31.4%8.0%-10.4%-38.8%-140.9%-101.4%-129.8%-162.1%
FCF margin6.1%22.1%-18.3%-68.2%-61.8%-103.2%-108.3%-125.6%-180.1%
ROIC—9.1%5.4%-4.5%-9.7%-27.9%-19.0%-33.0%—
ROE—40.2%15.5%-18.2%-19.3%-65.2%-27.7%-61.4%12.4%

Frequently asked questions

What is TransMedics Group’s annual revenue?

$605M in fiscal 2025 and $728M over the twelve months to September 30, 2026.

How much profit does TransMedics Group make?

Net income was $190M in fiscal 2025 (net margin 31.4%).

Is TransMedics Group’s revenue growing?

Yes: revenue rose 37.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.